The intervention being tested is trastuzumab deruxtecan (T-DXd), a drug designed to treat HER2-low expressing breast cancer. T-DXd is administered intravenously at a recommended dose of 5.4 mg/kg ...

TOKYO & BASKING RIDGE, N.J., October 30, 2024--The first patients have been dosed in three global, randomized phase 3 trials evaluating the efficacy and safety of datopotamab deruxtecan (Dato-DXd ...

Datopotamab deruxtecan (Dato-DXd) Datopotamab deruxtecan (Dato-DXd) is an investigational TROP2-directed ADC. Designed using Daiichi Sankyo’s proprietary DXd ADC Technology, datopotamab deruxtecan is ...

Datopotamab deruxtecan is a specifically engineered TROP2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed by Daiichi Sankyo and ...

The Biologics License Application (BLA) seeking accelerated approval in the U.S. for Daiichi Sankyo (TSE: 4568) and Merck’s (NYSE: MRK), known as MSD outside of the United States and ...

Background: Trastuzumab deruxtecan (T-DXd) is a novel antibody-drug conjugate (ADC) showing significant promise in treatment of metastatic HER2+ and HER2-low breast cancer. This systematic review and ...

In the global, multicenter, phase 3 DESTINY-Breast09 study, Tolaney and colleagues randomly assigned 1,157 patients 1:1:1 to T-DXd plus pertuzumab (n = 383), taxane (paclitaxel or docetaxel) plus ...

AstraZeneca, in collaboration with Daiichi Sankyo, is conducting a Phase 3b clinical study titled ‘DESTINY-Breast15’ to evaluate the safety and efficacy of Trastuzumab Deruxtecan (T-DXd) in ...

CHICAGO — Second-line trastuzumab deruxtecan-nxki significantly extended OS compared with paclitaxel plus ramucirumab for patients with advanced gastric cancers previously treated with ...

The biologics license application (BLA) seeking accelerated approval for patritumab deruxtecan (HER3-DXd) for adult patients with previously treated, locally advanced/metastatic EGFR-mutated non-small ...

Patritumab deruxtecan (HER3-DXd; MK-1022) is an investigational HER3-directed antibody-drug conjugate (ADC) that is composed of a human immunoglobulin G1 monoclonal antibody to HER3 (patritumab) ...

Patritumab deruxtecan is a specifically engineered HER3 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo and being jointly developed by Daiichi Sankyo and Merck (MRK).